OCP 8101
Alternative Names: OCP-8101Latest Information Update: 28 Nov 2025
At a glance
- Originator Oncocross; Unknown
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for research development in Unspecified in South Korea
- 07 Oct 2021 Early research in Unspecified in South Korea (unspecified route) before October 2021 (Oncocross' pipeline, October 2021)